No results were found for your search. Please adjust your search term or broaden your search criteria.
Still can't find what you are looking for? We can prepare Custom Research for you.
Actemra (tocilizumab) is a monoclonal antibody used to treat immune disorders, such as rheumatoid arthritis, giant cell arteritis, and systemic juvenile idiopathic arthritis. It works by blocking the action of interleukin-6, a protein that plays a role in inflammation. Actemra is approved for use in adults and children, and is administered intravenously or subcutaneously.
The Actemra market is a subset of the larger immune disorders drugs market. It is a growing market, driven by the increasing prevalence of autoimmune diseases and the need for effective treatments. Actemra is a key player in this market, as it is the only approved treatment for certain conditions, such as giant cell arteritis.
Companies in the Actemra market include Roche, which manufactures and markets the drug, as well as other pharmaceutical companies that develop and market treatments for immune disorders. Show Less Read more
